Wendy is a co-founder of Toronto based Ripple Therapeutics, spun out of Interface Biologics (IBI) in 2020. Wendy has been leading teams in the development of local drug delivery products for over 20 years. Wendy returned to Canada in 2016 to lead IBI’s drug delivery development. Prior to joining IBI, Wendy led the Clinical and Preclinical Programs for the development of a drug-eluting, self-expanding, biodegradable scaffold at a Bob Langer/George Whitesides Startup in Boston. Wendy began her industry career at Boston Scientific in the Corporate R&D group, which developed the TAXUS® Drug Eluting Stent. At Boston Scientific her work spanned developing combination products to deliver angiogenic biological agents to leading Regulatory Submission Strategies for approval of Class III combination products. Wendy received her PhD in Biomaterials from the University of Toronto and began developing her career interest in local drug delivery at Caltech during her post-doctoral fellowship. Wendy is an inventor of 35 patents in the local drug delivery field.